NO971487D0 - 5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjon - Google Patents
5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjonInfo
- Publication number
- NO971487D0 NO971487D0 NO971487A NO971487A NO971487D0 NO 971487 D0 NO971487 D0 NO 971487D0 NO 971487 A NO971487 A NO 971487A NO 971487 A NO971487 A NO 971487A NO 971487 D0 NO971487 D0 NO 971487D0
- Authority
- NO
- Norway
- Prior art keywords
- ht1f
- mediated inhibition
- extravasation
- neurogenic
- neurogenic meningeal
- Prior art date
Links
- 102100036311 5-hydroxytryptamine receptor 1F Human genes 0.000 title 1
- 101710138086 5-hydroxytryptamine receptor 1F Proteins 0.000 title 1
- 206010015866 Extravasation Diseases 0.000 title 1
- 230000036251 extravasation Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000001272 neurogenic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/318,330 US5698571A (en) | 1994-10-05 | 1994-10-05 | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
| PCT/US1995/013010 WO1996011006A1 (fr) | 1994-10-05 | 1995-10-03 | INHIBITION INDUITE PAR 5-HTlF DE L'EXTRAVASATION MENINGIENNE NEUROGENE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO971487D0 true NO971487D0 (no) | 1997-04-02 |
| NO971487L NO971487L (no) | 1997-04-02 |
Family
ID=23237717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO971487A NO971487L (no) | 1994-10-05 | 1997-04-02 | 5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjon |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5698571A (fr) |
| EP (1) | EP0705600A1 (fr) |
| JP (1) | JPH08208516A (fr) |
| AU (1) | AU688168B2 (fr) |
| CA (1) | CA2159767A1 (fr) |
| CZ (1) | CZ93097A3 (fr) |
| HU (1) | HUT77885A (fr) |
| NO (1) | NO971487L (fr) |
| NZ (1) | NZ296252A (fr) |
| RU (1) | RU2183457C2 (fr) |
| TW (1) | TW492864B (fr) |
| UA (1) | UA44284C2 (fr) |
| WO (1) | WO1996011006A1 (fr) |
| ZA (1) | ZA958314B (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406859B1 (en) | 1992-01-08 | 2002-06-18 | Synaptic Pharmaceutical Corporation | DNA encoding a 5-HT 1F receptor and uses thereof |
| ES2151993T3 (es) * | 1995-06-23 | 2001-01-16 | Lilly Co Eli | 1,2,3,4-tetrahidro-9h-carbazoles 6-sustituidos y 10h-ciclohepta(7,6-b)indoles 7-sustituidos. |
| US5962473A (en) * | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
| US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| DE69725459T2 (de) * | 1996-08-28 | 2004-08-12 | Eli Lilly And Co., Indianapolis | Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane |
| AU4074897A (en) * | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
| GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
| EA200100182A1 (ru) * | 1998-07-27 | 2001-08-27 | Эли Лилли Энд Компани | Лечение состояний тревожности |
| GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
| US6255334B1 (en) * | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
| CA2327000C (fr) * | 2000-11-27 | 2006-05-09 | Terry Cassaday | Partie de chaise ou de lit permettant le stockage de donnees |
| ATE404193T1 (de) * | 2001-06-05 | 2008-08-15 | Ronald Aung-Din | Topische migränetherapie |
| US8329734B2 (en) * | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
| TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| EP1575566B1 (fr) * | 2002-12-26 | 2012-02-22 | Pozen, Inc. | Formes galeniques multicouches contenant de naproxene et des triptanes |
| CA2529528A1 (fr) * | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes |
| CA2569964A1 (fr) * | 2004-06-10 | 2005-12-29 | Duramed Pharmaceuticals, Inc. | Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations |
| CA2585857A1 (fr) | 2004-11-26 | 2006-06-01 | Janssen Pharmaceutica N.V. | Derives d'isoxazoline-indole avec effet antipsychotique et anxiolytique ameliore |
| WO2010005507A1 (fr) | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Traitement neuro-affectif régional topique |
| WO2010115125A2 (fr) | 2009-04-02 | 2010-10-07 | Colucid Pharmaceuticals, Inc. | Composition à base de 2,4,6-trifluoro-n-[6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide |
| WO2011123654A1 (fr) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions et méthodes de synthèse d'agonistes des récepteurs 5-ht1f dérivés de la pyridinoylpipéridine |
| AU2016226267A1 (en) | 2015-03-02 | 2017-09-28 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
| TWI826514B (zh) * | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| TWI776175B (zh) | 2019-07-09 | 2022-09-01 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| US5360735A (en) * | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
-
1994
- 1994-10-05 US US08/318,330 patent/US5698571A/en not_active Expired - Fee Related
-
1995
- 1995-03-10 UA UA97041603A patent/UA44284C2/uk unknown
- 1995-10-03 TW TW084110318A patent/TW492864B/zh active
- 1995-10-03 JP JP7256141A patent/JPH08208516A/ja active Pending
- 1995-10-03 HU HU9702287A patent/HUT77885A/hu unknown
- 1995-10-03 RU RU97105384/14A patent/RU2183457C2/ru not_active IP Right Cessation
- 1995-10-03 ZA ZA958314A patent/ZA958314B/xx unknown
- 1995-10-03 CA CA002159767A patent/CA2159767A1/fr not_active Abandoned
- 1995-10-03 EP EP95306998A patent/EP0705600A1/fr not_active Withdrawn
- 1995-10-03 AU AU39996/95A patent/AU688168B2/en not_active Ceased
- 1995-10-03 WO PCT/US1995/013010 patent/WO1996011006A1/fr not_active Ceased
- 1995-10-03 NZ NZ296252A patent/NZ296252A/en unknown
- 1995-10-03 CZ CZ97930A patent/CZ93097A3/cs unknown
-
1997
- 1997-04-02 NO NO971487A patent/NO971487L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ296252A (en) | 1999-10-28 |
| RU2183457C2 (ru) | 2002-06-20 |
| WO1996011006A1 (fr) | 1996-04-18 |
| HUT77885A (hu) | 1998-09-28 |
| NO971487L (no) | 1997-04-02 |
| CA2159767A1 (fr) | 1996-04-06 |
| AU688168B2 (en) | 1998-03-05 |
| JPH08208516A (ja) | 1996-08-13 |
| ZA958314B (en) | 1997-04-03 |
| US5698571A (en) | 1997-12-16 |
| AU3999695A (en) | 1996-05-02 |
| TW492864B (en) | 2002-07-01 |
| MX9702478A (es) | 1997-07-31 |
| UA44284C2 (uk) | 2002-02-15 |
| CZ93097A3 (en) | 1997-09-17 |
| EP0705600A1 (fr) | 1996-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO971487D0 (no) | 5-HT1F-formidlet inhibering av neurogenisk hjernehinne-ekstravasjon | |
| DE69513175D1 (de) | Hydrathemmung | |
| DE69505829D1 (de) | Schale-bauteil zum korrosionsschutz von einspritzventilen | |
| DE69322141D1 (de) | Korrosionsinhibierende Zusammensetzung | |
| NO931947L (no) | Fremgangsmaate for korrosjons-hemming | |
| FI971635L (fi) | Menetelmät neuropeptidiin Y liittyvien tilojen inhiboimiseksi | |
| FI951554A0 (fi) | Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita | |
| FI963597L (fi) | Isoprenyylitransferaasi-inhibiittoreita | |
| NO972930D0 (no) | Fibronectin-adhesjonsinhibitorer | |
| FI972160A0 (fi) | Matriisimetalloproteaasi-inhibiittorit | |
| IT1295008B1 (it) | Combinazione di stabilizzanti | |
| ID24638A (id) | Senyawa-senyawa anti aritmia bispidina | |
| FI971784A0 (fi) | Apolipoproteiini B-synteesin estäjiä | |
| DK0815348T3 (da) | Hydrathæmning | |
| EE9700093A (et) | Apolipoproteiin-B sünteesi inhiibitorid | |
| EP0781326A4 (fr) | Famille des genes irs | |
| FI971632A7 (fi) | 5-lipoksygenaasin inhibiittoreita | |
| FI964781A7 (fi) | Uusia elastaasi-inhibiittoreita | |
| DE69433141D1 (de) | Zusammensetzungen aus kohleteerschlamm | |
| FI953170A7 (fi) | Oligunokleotidit isoprenyyliproteiinitransferaasin ilmentämisen inhibiboimiseksi | |
| ID17424A (id) | Penghambat matriks metaloproteasa oleh senyawa-senyawa fenetil tersubstitusi | |
| NO990116L (no) | Korrosjonsinhibering | |
| NO914123L (no) | Fremgangsmaate for korrosjonsbeskyttelse av j-roer | |
| IS4339A (is) | Hömlun ljóssundurliðunar á 3-setnum-2-oxindólum | |
| DE69735249D1 (de) | Bindungsinhibition des H-Komplementfaktors |